Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Subscribe To Our Newsletter & Stay Updated
